Tulobuterol Hydrochloride
PreclinicalSmall molecule
Tulobuterol Hydrochloride is one of 10 small molecule programs targeting Pediatric Patients. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Pediatric Patients
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
Blood Withdrawn
Emergent BioSolutionsPhase 3
Nsaids
RochePhase 3
Lexiscan
AstellasPhase 2
Bupivacaine Liposome
Pacira Pharmaceuticals, IncPhase 3
Joenja
PPharming Technologies B.V.
Phase 3
FCN-159
SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
Local Anaesthetic
CCali Pharmaceuticals LLC
Preclinical
Tulobuterol Hydrochloride
SSeoul National University Hospital
Preclinical
Glycolic Acid
UUniversity of Pennsylvania
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tulobuterol Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details